Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INCCPIX · Entity 6757 | Director | March 18, 2026 | March 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CUMBERLAND PHARMACEUTICALS INC
Report date March 18, 2026 · Filed March 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,300 |
Reported balance
After 2026-03-18 transaction · row 1
1 source rowRow 1 · 2026-03-18 · Grant · Acquired 1,800 · Balance 10,300 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 18, 2026 Filed Mar 20, 2026 21:24 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 1,800 | $2.80 | $5,040.00 |
DisclosureSEC source: 0001087294-26-000040 · wk-form4_1774041843.xml · nonDerivative · entry 1 Brown Martin S JR · CIK 0001362521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,300 Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 21:12 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 1,000 | $5.17 | $5,170.00 |
DisclosureSEC source: 0001628280-25-013538 · wk-form4_1742332351.xml · nonDerivative · entry 1 Brown Martin S JR · CIK 0001362521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 F1 · shares: Restricted stock award will vest 100% on March 17, 2026. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 00:29 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 1,000 | $1.71 | $1,710.00 |
DisclosureSEC source: 0001214659-24-005219 · marketforms-65377.xml · nonDerivative · entry 1 Brown Martin S JR · CIK 0001362521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 F1 · shares: Restricted stock award will vest 100% on March 25, 2025. Read SEC document |
| March 25, 2024 Filed Jan 30, 2025 21:40 UTC Amendment | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 2,500 | $1.71 | $4,275.00 |
DisclosureSEC source: 0001628280-25-003186 · wk-form4a_1738273215.xml · nonDerivative · entry 1 Brown Martin S JR · CIK 0001362521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 F1 · shares: This amendment is being filed solely to correct an administrative error in reporting the number of Securities Acquired by Reporting Owner on the original Form 4 submitted on March 26, 2024, which were reported as 1,000 shares granted on March 25, 2024, but should have been reported as 2,500 shares. This reflects an increase of 1,500 shares. Read SEC document |
| March 24, 2023 Filed Mar 27, 2023 21:41 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 1,000 | $1.97 | $1,970.00 |
DisclosureSEC source: 0001209191-23-021280 · doc4.xml · nonDerivative · entry 1 Brown Martin S JR · CIK 0001362521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Restricted stock award will vest 100% on March 24, 2024 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.